Clinical Trial Update: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating panitumumab and RAS mutation status as a diagnostically useful biomarker in metastatic colorectal cancer has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Takeda | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-11-01